

Attorney Docket No.: 5665.400-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Nørregaard-Madsen et al. Confirmation No: 3499

Serial No.: 09/652,743

Group Art Unit: 1652

Filed: August 31, 2000

Examiner: W. Moore

For: Proteases and Variants Thereof

#13
12/19/02**INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97(c)**Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.


While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art". The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The reference is listed in Form PTO/SB/08A, which is in accordance with the requirements of M.P.E.P. 609. The reference was cited in US application no. 09/551,826 filed April 17, 2000, the benefit of which is claimed under 35 USC 120. It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein.

The fee for filing this Information Disclosure Statement is set forth in 37 C.F.R. § 1.17(p). Please charge the fee, estimated to be \$180.00, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this charge directive is attached.

Respectfully submitted,

Date: December 3, 2002


Elias J. Lambins, Reg. No. 33,728
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097

12/19/2002 GTRAMMEL 00000003 501701 09652743

01 FC:1806 180.00 CH

